• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Impaired coagulation, liver dysfunction and COVID-19 : Discovering an intriguing relationship

    2022-03-31 08:07:28DamianoArdesAndreaBoccatondaGiulioCoccoStefanoFabianiIlariaRossiMarcoBucciMariaTeresaGuagnanoCosimaSchiavoneFrancescoCipollone
    World Journal of Gastroenterology 2022年11期

    Damiano D'Ardes, Andrea Boccatonda, Giulio Cocco, Stefano Fabiani, Ilaria Rossi,Marco Bucci,,Maria TeresaGuagnano,Cosima Schiavone,Francesco Cipollone

    Abstract Coronavirus disease 2019 (COVID-19 ) is, at present, one of the most relevant global health problems. In the literature hepatic alterations have been described in COVID-19 patients, and they are mainly represented by worsening of underlying chronic liver disease leading to hepatic decompensation and liver failure with higher mortality. Several potential mechanisms used by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ) to cause liver damage have been hypothesized. COVID-19 primary liver injury is less common than secondary liver injury. Most of the available data demonstrate how liver damage in SARSCoV-2 infection is likely due to systemic inflammation, and it is less likely mediated by a cytopathic effect directed on liver cells. Moreover, liver alterations could be caused by hypoxic injury and drugs (antibiotics and non-steroidal antiinflammatory drugs, remdesivir, tocilizumab, tofacitinib and dexamethasone).SARS-CoV-2 infection can induce multiple vascular district atherothrombosis by affecting simultaneously cerebral, coronary and peripheral vascular beds. Data in the literature highlight how the virus triggers an exaggerated immune response,which added to the cytopathic effect of the virus can induce endothelial damage and a prothrombotic dysregulation of hemostasis. This leads to a higher incidence of symptomatic and confirmed venous thrombosis and of pulmonary embolisms,especially in central, lobar or segmental pulmonary arteries, in COVID-19 . There are currently fewer data for arterial thrombosis, while myocardial injury was identified in 7 %-17 % of patients hospitalized with SARS-CoV-2 infection and 22 %-31 % in the intensive care unit setting. Available data also revealed a higher occurrence of stroke and more serious forms of peripheral arterial disease in COVID-19 patients. Hemostasis dysregulation is observed during the COVID-19 course. Lower platelet count, mildly increased prothrombin time and increased Ddimer are typical laboratory features of patients with severe SARS-CoV-2 infection, described as“COVID-19 associated coagulopathy.” These alterations are correlated to poor outcomes.Moreover, patients with severe SARS-CoV-2 infection are characterized by high levels of von Willebrand factor with subsequent ADAMTS13 deficiency and impaired fibrinolysis. Platelet hyperreactivity, hypercoagulability and hypofibrinolysis during SARS-CoV-2 infection induce a pathological state named as “immuno-thromboinflammation.” Finally, liver dysfunction and coagulopathy are often observed at the same time in patients with COVID-19 . The hypothesis that liver dysfunction could be mediated by microvascular thrombosis has been supported by postmortem findings and extensive vascular portal and sinusoidal thrombosis observation. Other evidence has shown a correlation between coagulation and liver damage in COVID-19 , underlined by the transaminase association with coagulopathy, identified through laboratory markers such as prothrombin time, international normalized ratio, fibrinogen, D-dimer, fibrin/fibrinogen degradation products and platelet count. Other possible mechanisms like immunogenesis of COVID-19 damage or massive pericyte activation with consequent vessel wall fibrosis have been suggested.

    Key Words: COVID-19 ; SARS-CoV-2 ; Liver; Coagulation

    lNTRODUCTlON

    Coronavirus disease 2019 (COVID-19 ) is, at present, one of the most relevant global health problems,declared a pandemic on March 11 , 2020 by the World Health Organization[1 ]. It is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2 ), a novel positive-sense single-stranded RNA betacoronavirus[2 ,3 ]. The pulmonary manifestation of COVID-19 , including pneumonia and acute respiratory distress syndrome, are well known, but it is necessary to emphasize that the coronavirus deleterious effects are also exerted on many other organ systems and are responsible for extrapulmonary manifestations[4 ].

    SARS-CoV-2 can cause both direct and indirect cardiovascular sequelae (myocardial injury, acute coronary syndromes, cardiomyopathy, acute cor pulmonale, arrhythmias and cardiogenic shock), acute kidney injury and gastrointestinal symptoms, such as diarrhea, nausea, vomiting, abdominal pain and anorexia[4 ]. Neurological complications include headaches, dizziness, ageusia, myalgia, anosmia up to stroke, Guillain-Barré and encephalopathy, and dermatological signs have also been described(petechiae, urticaria, vesicles, erythematous rash, livedo reticularis)[4 ]. Hepatobiliary manifestations can be observed especially in patients with severe presentations of COVID-19 and occur mainly with increased plasma levels of transaminases and bilirubin[4 ]. Thromboembolic events have also been described in COVID-19 , such as acute limb ischemia, which can occur in patients without existing peripheral arterial disease and in those receiving thromboprophylaxis. Acute abdominal-thoracic aortic thrombosis and mesenteric ischemia are less common but associated with significant morbidity and mortality[5 ]. Several studies have also demonstrated increased rates of deep vein thrombosis and pulmonary embolism in COVID-19 patient[5 -7 ]. Acute cerebrovascular disease, including ischemic stroke, and disseminated intravascular coagulation are also severe thrombotic complications of COVID-19 that must not be forgotten[5 ].

    This article aims to explore the possible mechanisms underlying hepatic and hemocoagulative alterations in COVID-19 through the search of published, readily accessible, peer-reviewed, full articles related to this topic written in English and found on PubMed.

    COVlD-19 AND LlVER

    Pathophysiology

    SARS-CoV-2 has the capacity to infect cells through the angiotensin-converting enzyme 2 (ACE2 )receptor that is mainly expressed on the type 2 alveolar cells[8 ]. The ACE2 receptor is mainly present in the liver, lung, heart, renal and gastrointestinal system[9 ]. Regarding hepatic involvement, the level of ACE2 expression in cholangiocytes (59 .7 %) is higher than hepatocytes (2 .9 %)[10 ]. SARS-CoV-2 cell entry is mediated by its S protein, which specifically interacts with the host cell ACE2 and transmembrane serine protease 2 [11 ]. The major expression of ACE2 in cholangiocytes reveals that SARS-CoV-2 may cause bile duct dysfunction. Cholangiocytes play critical roles in liver regeneration and immune responses, indicating that viral immunologic injury might be important in liver injury in COVID-19 [12 ].

    Even if there is a substantial difference in ACE2 receptor expression between the liver and biliary tract, the liver is not unaffected by the SARS-CoV-2 infection. In fact, current data have shown that in patients with COVID-19 aspartate aminotransferase (AST), alanine aminotransferase (ALT) and lactate dehydrogenase levels are increased, while alkaline phosphatase and gamma glutamyl transferase,representatives of bile duct injury, did not increase significantly[12 ]. Indeed, in the literature many clinical findings and hepatic alterations are described, and there are several reported potential mechanisms used by the virus to cause liver disease.

    Most of the available data demonstrate that hepatic injury during SARS-CoV-2 infection is more likely due to systemic inflammation, and it is less likely mediated by a cytopathic effect directed on liver cells. Viral RNA can be detected in liver tissue of patients with COVID-19 , but infection of liver cells has not yet been demonstrated[13 ]. During a viral infection, the innate and the acquired immune systems recognize pathogen associated molecular patterns and specific viral antigens and release inflammatory molecules, such as cytokines and chemokines, that activate macrophages and T cells to clear the virus and kill infected cells. In patients affected by COVID-19 , high levels of inflammatory cytokines have been observed, and this context could cause significant liver damage when SARS-CoV-2 infects host hepatocytes. The most involved inflammatory molecules are tumor necrosis factor, interleukin-2 (IL-2 ),IL-6 , IL-7 , IL-18 , granulocyte-colony stimulating factor, interferon-γ and ferritin[14 ]. An early hypercytokinemia could lead to multiorgan injuries, including the liver (Figure 1 ). The literature demonstrates that worse outcomes of COVID-19 are more common in patients with early cytokine elevation[15 ].

    Another potentially harming mechanism is represented by hypoxic injury. The complex vascularization of the liver makes it particularly exposed to circulatory alterations that could be generated in cardiac, circulatory, respiratory failure or in septic shock, causing decreased perfusion of the liver[12 ].About 1 .1 %-20 .0 % of COVID-19 patients are affected by septic shock, and 23 .0 % of patients have heart failure[16 ].

    Drugs are also involved with damage mechanisms, particularly causing drug induced liver injury.Antibiotics and non-steroidal anti-inflammatory drugs, which are one of the most common causes of drug induced liver injury in the general population, can contribute to liver damage in COVID-19 patients when used to treat bacterial superinfection, myalgias or fever. Furthermore, drug induced liver injury has been shown in 15 .2 % of patients receiving remdesivir and in 37 .2 % of patients in treatment with lopinavir/ritonavir[17 ]. Finally, dexamethasone, tocilizumab and tofacitinib, used to treat COVID-19 , could potentially create hepatic injuryviapre-existing chronic liver disease reactivation, especially hepatitis B virus[18 ].

    Clinical characteristics

    During SARS-CoV-2 infection, patients can be asymptomatic or present clinical symptoms such as fever,dry cough, headache, dyspnea and fatigue and up to acute respiratory distress syndrome, shock and cardiac failure[19 ,20 ]. Hepatic involvement can occur through all the pathophysiological pathways previously investigated and still other studies are needed to better characterize them. In current reports,COVID-19 primary liver injury is less common than secondary liver injury[21 ,22 ]. SARS-CoV-2 liver involvement is mainly represented by worsening of underlying chronic liver disease, leading to hepatic decompensation and acute-on-chronic liver failure, with higher mortality. Symptoms mainly reported in the literature associated to liver injury and gastrointestinal involvement are diarrhea, nausea, vomiting and loss of appetite. Abnormal liver function was also observed with the increase of AST, ALT, lactate dehydrogenase and bilirubin and the decrease of albumin[21 -25 ].

    According to the current data, hepatic dysfunction is significantly higher in critically ill patients and is associated with a poor outcome, underlining its importance in clinical settings. Elevated liver enzymes are observed predominantly in severe and critical cases of COVID-19 . For example, increased AST was observed in 62 % of patients in the intensive care unit (ICU) compared to 25 % in non-ICU patients[23 ]. Chen et al[21 ] reported that AST, ALT, alkaline phosphatase, gamma glutamyl transferase and bilirubin levels were significantly higher in non-survivors than in survivors. Also hypoalbuminemia was found significantly lower in deceased patients rather than in surviving patients.Furthermore, according to Bangashet al[24 ] the mortality rate in patients with underlying chronic liver disease was 0 %-2 %. According to the literature data, liver injury is most common in critically ill patients who have diabetes and hypertension[22 ,25 ].

    Figure 1 Structure of severe acute respiratory syndrome coronavirus 2 hepatic receptors that induce hepatic injury mediated by cytokine storm. Inflammatory mediators secreted by lymphocytes and macrophages aggravate inflammatory responses causing hepatic damage. IL: Interleukin; GC-SF:Granulocyte colony stimulating factor; ACE-2 : Angiotensin-converting enzyme 2 .

    The fact that liver injury in COVID-19 is mostly hepatocellular rather than cholestatic is demonstrated by the more frequent elevation of ALT, AST and lactate dehydrogenase than of alkaline phosphatase and gamma glutamyl transferase. The latter two did not increase significantly, and jaundice is uncommon[12 ,26 ]. Moreover, the current data demonstrate that AST could represent an important hepatocellular injury marker because its elevation is associated with a major mortality risk[27 ].According to a meta-analysis, the pooled prevalence of abnormal liver functions (12 studies, 1267 patients) was 19 %, and in subgroup analysis patients with severe COVID-19 had higher rates of abdominal pain and abnormal liver function including increased ALT and AST[28 ].

    In a hospital setting, drugs also have to be considered in liver injury; moreover COVID-19 critically ill patients are treated with multiple drugs, such as antibiotics, immunosuppressants and antiviral and antipyretic agents that are associated to abnormal liver function, especially when used in patients with severe COVID-19 [23 ,29 ]. In the literature, drug induced liver injury has been shown to result in AST and ALT elevation and reactivation of pre-existing chronic liver disease, above all hepatitis B virus infection[17 ,18 ]. Indeed, a retrospective study has shown that patients with chronic hepatitis B virus hepatitis had a worse prognosis for COVID-19 and for a higher mortality and a higher incidence of acute-on-chronic liver failure[30 ]. In a trial by Goldman et al[31 ] comparing remdesivir treatment for either 5 d or 10 d, severe but not life-threatening ALT/AST elevations were reported in 4 %-6 % of patients and life-threatening AST/ALT elevations in 2 %-3 % of patients.

    COVlD-19 AND COAGULATlON DlSORDERS

    Clinical characteristics

    SARS-CoV-2 infection can induce multiple vascular district atherothrombosis by simultaneously affecting cerebral, coronary and peripheral vascular beds. Data in the literature highlight how the virus can trigger an exaggerated immune response, which added to the cytopathic effect of the virus can induce endothelial damage and a prothrombotic dysregulation of hemostasis[32 -34 ]. Nowadays, there are several reports and original papers on cases of venous thromboembolism and pulmonary embolism related to COVID-19 [35 -40 ].

    Incidence of symptomatic and confirmed venous thrombosis in COVID-19 patients hospitalized in the ICU can reach 30 %-40 %[41 ]. Data from a study performed in China demonstrated that 25 % of COVID-19 patients developed lower extremity deep vein thrombosis without venous thromboembolism prophylaxis[42 ]. A work by Klok et al[36 ] described pulmonary embolisms in 25 of 184 ICU patients with COVID-19 (13 .6 %), 72 % of which were in central, lobar or segmental pulmonary arteries, despite standard dose pharmacological prophylaxis[36 ,43 ]. In Italy, Lodigiani et al[35 ] showed thromboembolic events (venous and arterial) in 7 .7 % of patients admitted with COVID-19 , corresponding to a cumulative rate of 21 .0 %.

    There are currently fewer data for arterial thrombosis. A study from Wuhan showed that about 12 %of patients displayed Hs-troponin I above the threshold of 28 pg/mL[14 ]. Other data revealed that myocardial injury was diagnosed in 7 %-17 % of patients hospitalized with SARS-CoV-2 infection and 22 %-31 % in the ICU setting[16 ,25 ]. Dysregulated inflammatory response enhances atherosclerotic plaque disruption[21 ,44 -46 ]. Previous studies demonstrated that influenza and community-acquired pneumonia are related to an increased risk of myocardial infarction, within the first 7 d of diagnosis and even after hospitalization[47 ]. Regarding cerebrovascular disease, occurrence of stroke in COVID-19 patients ranges between 2 .7 % and 3 .8 %, and these subgroup of patients often displayed comorbidities such as hypertension and were older on average[48 ,49 ]. Moreover, there are some reports documenting more serious forms of peripheral arterial disease in patients with SARS-CoV-2 infection[50 ].

    Laboratory findings

    Hemostasis dysregulation has been described as an early pathological change in the COVID-19 course.Lower platelet count, mildly increased prothrombin time and increased D-dimer are typical laboratory features of patients with severe SARS-CoV-2 infection, and they are correlated to poor outcomes[51 ].Those changes have been described as “COVID-19 associated coagulopathy”[52 -54 ]. Moreover, patients with severe SARS-CoV-2 infection are characterized by high levels of IL-6 , thus leading to a subsequent increase in proteins such as fibrinogen and von Willebrand factor (vWF)[55 ]. High lactate dehydrogenase and ferritin values are other laboratory findings of patients with severe COVID-19 infection,resembling a thrombotic microangiopathy[51 ,55 ,56 ]. Furthermore, complement components C5 b-9 , C4 d and mannose-binding lectin-associated serine protease 2 have been detected in the small vessels of the lung due to complement-associated microvascular injury[57 ]. High levels of vWF and subsequent ADAMTS13 deficiency seem to be other typical findings of severe COVID-19 infection[52 ,58 ,59 ].Decreased levels of ADAMTS13 can induce increased platelet-endothelial interaction generating a thrombotic microangiopathy-like state[52 ,60 -63 ].

    Recent data demonstrate that fibrinolysis is impaired in patients with severe COVID-19 [64 ,65 ].Critical COVID-19 patients are characterized by low levels of plasminogen, as for a consumptive state[65 ]. Nougier et al[66 ] reported elevated levels of plasminogen activator inhibitor 1 and low levels of tissue plasminogen activator, along with high thrombin generation, thus demonstrating a significant imbalance between inhibitor and activator factors of fibrinolysis.

    Pathogenetic mechanisms

    Platelet hyperreactivity, hypercoagulability and hypofibrinolysis induce a pathological state that has been named “immuno-thromboinflammation” during SARS-CoV-2 infection[67 ]. SARS-CoV-2 binds to the ACE2 receptor on the surface of endothelial and arterial smooth muscle cells, inducing a cytopathic effect and a subsequent endothelial injury[68 ]. As it is well known, endothelial damage triggers platelet activation, adhesion to the subendothelial matrix and aggregation, thus generating a platelet plug[69 ].Moreover, a release of vWF, inefficient cleavage of ultralarge vWF catalyzed by ADAMTS13 , direct contact with activating surfaces in the subendothelial matrix, loss of heparan sulfates at the surface of injured blood vessels, disrupted generation of nitric oxide, prostaglandin E2 and prostaglandin I2 and loss of surface expression of ectonucleotidases occur[70 ,71 ]. Platelet activation may represent a consequence of the production of a consistent level of thrombin after initiation of coagulation[64 ].

    Furthermore, high IL-6 levels can induce megakaryocytopoiesis generation and platelet formation,which could play a role to generate a hypercoagulability state, in particular within the lung. Intriguing,SARS-CoV-2 can bind directly to platelets since they express both ACE2 and transmembrane serine protease 2 on their surface[72 ]; this binding can favor platelet activation and the release of clotting factors, inflammatory molecules and leukocyte-platelet aggregates[72 ].

    In patients affected by severe COVID-19 pneumonia, levels of tissue factor (TF) on monocytes are higher than normal, together with P-selectin expression and the amount of platelet-neutrophil and platelet-monocyte aggregates[2 ]. Therefore, platelet activation due to adenosine diphosphate, thrombin and collagen stimulation is enhanced in these patients. Platelet hyperactivation induced by SARS-CoV-2 infection induce the release of inflammatory molecules such as cytokines, chemokines, growth factors and even procoagulant factors like fibrinogen and vWF[73 ]. This mechanism seems to generate a vicious cycle since inflammatory molecules worsen endothelial injury by decreasing nitric oxide availability and enhancing oxidative stress and/or favoring leukocyte-endothelial interaction[74 ,75 ].

    Endothelial injury triggers the release of TF in the blood stream. Moreover, TF can derive from macrophage/monocyte cells and through their microparticles, as a consequence of macrophage activation syndrome shown in patients with severe COVID-19 infection[76 ]. SARS-CoV-2 can directly induce macrophage activation, which can even occur as a consequence of the inflammatory hyperactivation (cytokine storm), as demonstrated by high levels of interferon-g, C-C motif chemokine ligand 2 and C-X-C motif chemokine 9 and 10 detected in critical COVID-19 patients[77 ,78 ].

    Neutrophils can also be activated both directly by SARS-CoV-2 and by other inflammatory cells, thus generating neutrophil extracellular traps that may activate Factor XII and the intrinsic pathway of coagulation[79 ]. Hemostasis dysregulation in SARS-CoV-2 infection is also characterized by a decreased activity of endogenous anticoagulants like antithrombin, TF pathway inhibitor and anticoagulation proteins C and S[78 ,80 ]. Endothelial injury and platelet hyper-activation in severe COVID-19 patients enhance the release of plasminogen activator inhibitor 1 (PAI-1 )[81 ]. High levels of PAI-1 can further inhibit fibrinolysis, thus worsening the thrombotic burden[82 ,83 ]. Therefore, as the pulmonary inflammation progresses, there is consumption of plasminogen, along with high levels of PAI-1 and depletion of tPA, thus inducing a state of hypofibrinolysis and allowing perpetuation of prothrombotic state[84 ].

    In patients with SARS-CoV-2 infection, the presence of antiphospholipid antibodies has been demonstrated, which may directly induce endothelial cell activation and enhance TF expression by monocytes, thus contributing to the procoagulant and prothrombotic state[85 -87 ]. Particularly, antiphospholipid antibodies can bind to the platelets and trigger their activation decreasing levels of inhibitors such as activated protein C and antithrombin and increasing clotting factors such as FXa and thrombin[88 -90 ].

    SARS-CoV-2 can dysregulate the ACE pathway by its binding to the ACE2 receptor on tissues; high levels of angiotensin (Ang) II favor PAI-1 and TF expression, thus promoting hypercoagulability and impairing fibrinolysis[60 ]. Furthermore, Ang II receptors on platelets can induce platelet activation and aggregation[91 ]. Ang 1 ,7 levels are lower in COVID-19 patients who develop severe disease[92 ]. Ang 1 ,7 is a vasoprotective molecule by mediating vasodilation and blocking platelet aggregation through nitric oxide release[93 -95 ]. Therefore, low Ang 1 ,7 levels can contribute to the procoagulant state in COVID-19 infection. Finally, obesity is a main risk factor for thrombosis due to adipocytokine-mediated mechanisms, increased inflammatory molecules, Ang II/Ang 1 ,7 imbalance, reactive oxygen speciesmediated endothelial dysfunction and lipid and glucose metabolism changes[96 -98 ].

    RELATlONSHlP BETWEEN COVlD-19 , LlVER AND COAGULATlON

    Liver dysfunction and coagulopathy are often observed in patients with COVID-19 . Japanese researchers found that patients with high ALT had higher levels of D-dimer and fibrin/fibrinogen degradation products. In particular elevation of ALT and D-dimer were identified simultaneously[99 ].Moreover D-dimer was independently associated to ALT elevation[99 ].

    This study suggests the hypothesis that liver dysfunction could be mediated by microvascular thrombosis, and intrahepatic microvascular thrombosis could theoretically play a role in this physiopathological context. This hypothesis is supported by post-mortem findings by Sonzogniet al[100 ] who found marked derangement of intrahepatic blood vessels with aspects of intravascular thrombosis, suggesting a possible liver damage linked to thrombotic processes. Other evidence has shown a correlation between coagulation and liver damage in COVID-19 . In fact, a Chinese study on COVID-19 patients demonstrated the association between AST and ALT values with coagulopathy,identified through laboratory markers such as prothrombin time, international normalized ratio,fibrinogen, D-dimer and platelet count[101 ]. Pathological findings are consistent with a vascular-related damage caused by impaired blood flow, with lesions similar to histological characteristics of hepatopulmonary syndrome and in obliterative portal venopathy[100 ]. Indeed it has been shown a diffuse network of sinusoids decorated by CD34 suggesting an abnormal hepatic circulation of blood[100 ].

    A likely explanation could be related to increased hepatic blood flow: this aspect may be linked to heart distress or to thrombotic phenomena in portal and sinusoidal vessels[100 ]. The abnormal high levels of transaminases in some patients whose liver sample were analyzed post-mortem could be explained by extensive vascular portal and sinusoidal thrombosis, leading to confluent parenchymal necrosis and hepatic cells accelerating apoptosis[100 ]. Attention must be paid to the evidence of massive pericyte activation in liver samples obtained post-mortem[100 ]. Pericytes are involved in the recruitment of inflammatory cells in liver injury, and their transformation in myofibroblast-like cells leads to the production of abundant amounts of extracellular matrix proteins and to the consequent vessel wall fibrosis[100 ].

    CONCLUSlON

    Liver abnormalities and coagulopathy are physiopathological characteristics of COVID-19 that represent the most relevant global health problem. Hypercoagulability, hypofibrinolysis and platelet alterations during SARS-CoV-2 infection induce a sort of “immuno-thromboinflammation,” while mildly increased prothrombin time and increased D-dimer are typical laboratory features of patients with severe SARSCoV-2 infection, described as “COVID-19 associated coagulopathy.” These phenomena are clinically relevant with manifestations of thrombosis in a large variety of anatomic districts. Moreover, hepatic alterations are mainly represented by worsening of underlying chronic liver disease leading to hepatic decompensation and liver failure with higher mortality, and they appear to be mediated more by systemic inflammation, direct cytopathic effect on liver cells, hypoxic injury and drugs. Liver dysfunction and coagulopathy are also observed at the same time in patients with COVID-19 , probably mediated by microvascular thrombosis, immunological mechanisms and pericyte activation. More data are needed to better investigate the relevant relationship between coagulation, liver dysfunction and COVID-19 with the aim to understand more deeply the physiopathological mechanisms of SARS-CoV-2 and to evaluate new therapeutic strategies to prevent mortality.

    FOOTNOTES

    Author contributions:All authors have designed, written and revised the manuscript.

    Conflict-of-interest statement:There is no conflict of interest associated with the authors of this manuscript.

    Open-Access:This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BYNC 4 .0 ) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is noncommercial. See: https://creativecommons.org/Licenses/by-nc/4 .0 /

    Country/Territory of origin:Italy

    ORClD number:Damiano D’Ardes 0000 -0001 -5573 -4536 ; Andrea Boccatonda 0000 -0001 -9303 -7790 ; Giulio Cocco 0000 -0003 -3458 -5468 ; Stefano Fabiani 0000 -0001 -6821 -103 X; Ilaria Rossi 0000 -0001 -5163 -9929 ; Marco Bucci 0000 -0002 -5213 -7768 ; Maria Teresa Guagnano 0000 -0001 -7225 -0891 ; Cosima Schiavone 0000 -0002 -8453 -4936 ; Francesco Cipollone 0000 -0002 -5993 -9341 .

    S-Editor:Wu YXJ

    L-Editor:Filipodia

    P-Editor:Wu YXJ

    亚州av有码| 欧美成人午夜免费资源| 中文字幕久久专区| 大陆偷拍与自拍| 国产 一区精品| 国产精品三级大全| 简卡轻食公司| 国产高清三级在线| 伊人久久精品亚洲午夜| 亚洲熟女精品中文字幕| 有码 亚洲区| 高清欧美精品videossex| 中文字幕制服av| 亚洲无线观看免费| 在线观看免费日韩欧美大片 | 精华霜和精华液先用哪个| 97在线视频观看| 一本一本综合久久| 国产成人精品一,二区| 国产精品一区二区在线观看99| 免费人妻精品一区二区三区视频| 18禁在线播放成人免费| 天堂俺去俺来也www色官网| 成人一区二区视频在线观看| 日韩人妻高清精品专区| 伦理电影免费视频| 麻豆乱淫一区二区| 伦精品一区二区三区| 男人舔奶头视频| 亚洲自偷自拍三级| 在线 av 中文字幕| 国产伦精品一区二区三区四那| 天堂中文最新版在线下载| 色婷婷av一区二区三区视频| 久久国内精品自在自线图片| 日韩电影二区| 大话2 男鬼变身卡| 日本猛色少妇xxxxx猛交久久| 日韩欧美精品免费久久| 免费黄频网站在线观看国产| 身体一侧抽搐| 2018国产大陆天天弄谢| 在线观看美女被高潮喷水网站| 91在线精品国自产拍蜜月| 美女高潮的动态| 久久久欧美国产精品| 国产高潮美女av| 777米奇影视久久| 最近手机中文字幕大全| 亚洲av在线观看美女高潮| 岛国毛片在线播放| 少妇人妻 视频| 欧美zozozo另类| 国产精品伦人一区二区| 免费看光身美女| 欧美日韩在线观看h| 在线观看国产h片| 少妇 在线观看| 午夜免费观看性视频| 午夜福利网站1000一区二区三区| 欧美少妇被猛烈插入视频| 在线免费十八禁| 精品久久久噜噜| 在线天堂最新版资源| www.色视频.com| 卡戴珊不雅视频在线播放| 亚洲精品456在线播放app| 久久av网站| 自拍偷自拍亚洲精品老妇| 国产亚洲午夜精品一区二区久久| 天堂俺去俺来也www色官网| 18禁国产床啪视频网站| 欧美人与性动交α欧美精品济南到| 欧美大码av| 亚洲专区国产一区二区| 国产又色又爽无遮挡免| 成人黄色视频免费在线看| 欧美日韩视频高清一区二区三区二| 午夜两性在线视频| www.999成人在线观看| 国产精品偷伦视频观看了| 制服人妻中文乱码| 国产一级毛片在线| 看免费成人av毛片| 99久久精品国产亚洲精品| 午夜日韩欧美国产| 亚洲少妇的诱惑av| 欧美激情高清一区二区三区| 久久久国产一区二区| 在线 av 中文字幕| 日韩欧美一区视频在线观看| 中文欧美无线码| 中文字幕最新亚洲高清| 黄色 视频免费看| 日韩,欧美,国产一区二区三区| 国产熟女午夜一区二区三区| 热re99久久国产66热| av线在线观看网站| 在线看a的网站| www.精华液| 国产黄色视频一区二区在线观看| 一区二区日韩欧美中文字幕| 亚洲人成电影观看| 啦啦啦视频在线资源免费观看| 狠狠精品人妻久久久久久综合| 五月开心婷婷网| 精品国产一区二区久久| 欧美精品啪啪一区二区三区 | 国产在线观看jvid| 最近中文字幕2019免费版| 国产成人免费观看mmmm| 99国产精品一区二区三区| 精品亚洲成a人片在线观看| 男女之事视频高清在线观看 | 日韩制服丝袜自拍偷拍| 满18在线观看网站| 中国国产av一级| 国产精品国产三级国产专区5o| 亚洲成人国产一区在线观看 | 精品亚洲成a人片在线观看| 成年美女黄网站色视频大全免费| 亚洲国产中文字幕在线视频| 午夜激情av网站| 久久毛片免费看一区二区三区| 国产av精品麻豆| 久久精品亚洲av国产电影网| 国产成人a∨麻豆精品| 亚洲精品日本国产第一区| 免费黄频网站在线观看国产| 日韩大码丰满熟妇| 我的亚洲天堂| 91字幕亚洲| 90打野战视频偷拍视频| 操美女的视频在线观看| 亚洲五月色婷婷综合| 人妻一区二区av| 国产欧美日韩综合在线一区二区| 9191精品国产免费久久| 天天影视国产精品| 久久性视频一级片| 午夜福利影视在线免费观看| 1024香蕉在线观看| 精品国产一区二区久久| 精品少妇一区二区三区视频日本电影| videosex国产| 久久久国产一区二区| 午夜两性在线视频| 精品国产一区二区三区久久久樱花| 日韩中文字幕视频在线看片| 丰满饥渴人妻一区二区三| 国产欧美日韩精品亚洲av| 别揉我奶头~嗯~啊~动态视频 | 久久人人97超碰香蕉20202| 国产成人精品在线电影| 夫妻午夜视频| 亚洲专区中文字幕在线| av网站免费在线观看视频| 亚洲国产精品一区三区| 久久久国产欧美日韩av| 91国产中文字幕| 高清不卡的av网站| 男人添女人高潮全过程视频| 欧美人与性动交α欧美精品济南到| 9191精品国产免费久久| 宅男免费午夜| 桃花免费在线播放| 97人妻天天添夜夜摸| 欧美激情 高清一区二区三区| av福利片在线| 美女国产高潮福利片在线看| 久久精品国产亚洲av涩爱| 国产一区二区在线观看av| 日本欧美国产在线视频| 亚洲精品美女久久久久99蜜臀 | 人人妻,人人澡人人爽秒播 | 中文字幕精品免费在线观看视频| 人妻一区二区av| bbb黄色大片| 高清欧美精品videossex| 久久亚洲精品不卡| 精品一区二区三区四区五区乱码 | 国产三级黄色录像| 国产精品 欧美亚洲| 亚洲五月色婷婷综合| 视频区欧美日本亚洲| 大码成人一级视频| 中文字幕亚洲精品专区| 日韩av不卡免费在线播放| 制服人妻中文乱码| 国产野战对白在线观看| 国产精品一国产av| 午夜福利影视在线免费观看| 中文字幕人妻丝袜一区二区| 99热网站在线观看| 老汉色∧v一级毛片| 女性生殖器流出的白浆| 亚洲精品国产色婷婷电影| 国产欧美日韩一区二区三区在线| 男女边摸边吃奶| 亚洲色图综合在线观看| 国产免费又黄又爽又色| 久久久精品国产亚洲av高清涩受| 97人妻天天添夜夜摸| 岛国毛片在线播放| 久久影院123| 中文字幕亚洲精品专区| 日韩av在线免费看完整版不卡| 亚洲,一卡二卡三卡| 国产野战对白在线观看| 99香蕉大伊视频| 精品久久久精品久久久| 亚洲久久久国产精品| av片东京热男人的天堂| 热re99久久精品国产66热6| 99精国产麻豆久久婷婷| 50天的宝宝边吃奶边哭怎么回事| 精品亚洲乱码少妇综合久久| 大香蕉久久成人网| 精品福利观看| 国产av精品麻豆| 搡老乐熟女国产| 国产在线一区二区三区精| av网站免费在线观看视频| 亚洲国产毛片av蜜桃av| 国产精品九九99| 日韩 亚洲 欧美在线| 熟女少妇亚洲综合色aaa.| 9191精品国产免费久久| 十八禁高潮呻吟视频| 国产伦人伦偷精品视频| 夫妻午夜视频| 黄网站色视频无遮挡免费观看| 视频区欧美日本亚洲| 桃花免费在线播放| 老司机在亚洲福利影院| 欧美人与善性xxx| 人人妻人人澡人人看| 一本大道久久a久久精品| 巨乳人妻的诱惑在线观看| 男女之事视频高清在线观看 | 校园人妻丝袜中文字幕| 777久久人妻少妇嫩草av网站| 午夜福利一区二区在线看| 免费看十八禁软件| 午夜免费鲁丝| 黑人巨大精品欧美一区二区蜜桃| 久久国产精品大桥未久av| 美女扒开内裤让男人捅视频| 一级黄色大片毛片| 欧美日本中文国产一区发布| 99精品久久久久人妻精品| 欧美乱码精品一区二区三区| 免费少妇av软件| 视频在线观看一区二区三区| 欧美久久黑人一区二区| 在线观看www视频免费| 国产精品九九99| 最新在线观看一区二区三区 | 人妻 亚洲 视频| 国产精品国产三级专区第一集| 成人三级做爰电影| 美女国产高潮福利片在线看| 亚洲视频免费观看视频| 国产精品久久久久久人妻精品电影 | 99国产精品一区二区三区| 日本五十路高清| 国产在线免费精品| 亚洲一区二区三区欧美精品| www.精华液| 一级a爱视频在线免费观看| 在线观看免费视频网站a站| 看免费成人av毛片| 最新的欧美精品一区二区| 欧美日韩亚洲国产一区二区在线观看 | 色婷婷久久久亚洲欧美| 在线亚洲精品国产二区图片欧美| 午夜免费男女啪啪视频观看| 黄频高清免费视频| 性少妇av在线| 亚洲 欧美一区二区三区| 亚洲精品在线美女| 久久毛片免费看一区二区三区| 麻豆av在线久日| 亚洲成人手机| 热99久久久久精品小说推荐| 性少妇av在线| 中文字幕制服av| 欧美精品人与动牲交sv欧美| 精品久久久精品久久久| 亚洲国产日韩一区二区| 亚洲欧洲精品一区二区精品久久久| 亚洲专区中文字幕在线| 国产精品偷伦视频观看了| 精品久久久精品久久久| 成年人免费黄色播放视频| 777米奇影视久久| 久久久久久人人人人人| 日韩一本色道免费dvd| 99国产精品99久久久久| 欧美黄色片欧美黄色片| 熟女少妇亚洲综合色aaa.| 老司机靠b影院| 国产男人的电影天堂91| 国产欧美日韩一区二区三区在线| 一级片免费观看大全| 亚洲成人手机| 蜜桃在线观看..| 一区二区av电影网| 久久久久久免费高清国产稀缺| 丝袜美腿诱惑在线| 久久影院123| 午夜福利视频在线观看免费| 如日韩欧美国产精品一区二区三区| 亚洲精品国产av成人精品| 男女床上黄色一级片免费看| www.熟女人妻精品国产| 成人午夜精彩视频在线观看| 午夜激情久久久久久久| 国产淫语在线视频| 各种免费的搞黄视频| 悠悠久久av| 国产色视频综合| 欧美精品亚洲一区二区| 高清黄色对白视频在线免费看| 一本综合久久免费| 欧美日韩亚洲综合一区二区三区_| 一区二区三区四区激情视频| 国产欧美日韩精品亚洲av| 制服人妻中文乱码| 亚洲第一青青草原| av天堂久久9| 青春草视频在线免费观看| 色婷婷av一区二区三区视频| 涩涩av久久男人的天堂| 久9热在线精品视频| 97精品久久久久久久久久精品| 51午夜福利影视在线观看| 99久久99久久久精品蜜桃| 国产一区二区三区综合在线观看| 我的亚洲天堂| 欧美日本中文国产一区发布| 国产99久久九九免费精品| 人人妻人人爽人人添夜夜欢视频| 欧美日韩视频高清一区二区三区二| 1024香蕉在线观看| 青青草视频在线视频观看| 热99久久久久精品小说推荐| www.熟女人妻精品国产| 亚洲第一青青草原| 黄色a级毛片大全视频| 两个人免费观看高清视频| 美女扒开内裤让男人捅视频| avwww免费| 中文精品一卡2卡3卡4更新| 精品人妻一区二区三区麻豆| 十分钟在线观看高清视频www| 丝瓜视频免费看黄片| 国产欧美日韩综合在线一区二区| 在线亚洲精品国产二区图片欧美| 国产成人av教育| 在线亚洲精品国产二区图片欧美| 国产成人av教育| 亚洲 国产 在线| 黄色片一级片一级黄色片| 午夜视频精品福利| 黄色片一级片一级黄色片| 成年av动漫网址| 精品国产乱码久久久久久小说| 黄色 视频免费看| 国产熟女午夜一区二区三区| 狠狠精品人妻久久久久久综合| 美女主播在线视频| 亚洲图色成人| 精品一区二区三区四区五区乱码 | 十八禁人妻一区二区| a 毛片基地| 欧美xxⅹ黑人| 曰老女人黄片| 日韩一本色道免费dvd| 亚洲欧美精品综合一区二区三区| 日韩一本色道免费dvd| 狂野欧美激情性bbbbbb| 日韩一本色道免费dvd| 一级a爱视频在线免费观看| 久久免费观看电影| 一二三四在线观看免费中文在| 美女大奶头黄色视频| 日韩 亚洲 欧美在线| av网站免费在线观看视频| 亚洲欧美中文字幕日韩二区| 日韩av不卡免费在线播放| 亚洲专区国产一区二区| 香蕉国产在线看| 婷婷成人精品国产| 午夜av观看不卡| 亚洲国产欧美日韩在线播放| 日韩制服骚丝袜av| 涩涩av久久男人的天堂| 可以免费在线观看a视频的电影网站| 亚洲第一av免费看| 国产精品 欧美亚洲| 国产精品久久久人人做人人爽| 99热网站在线观看| 热re99久久精品国产66热6| 亚洲av日韩在线播放| 啦啦啦视频在线资源免费观看| 熟女av电影| www.精华液| 久久毛片免费看一区二区三区| 成人18禁高潮啪啪吃奶动态图| 黄片小视频在线播放| 久久综合国产亚洲精品| www.999成人在线观看| 亚洲精品av麻豆狂野| 欧美激情极品国产一区二区三区| 国产成人精品久久二区二区免费| 中文字幕另类日韩欧美亚洲嫩草| 97人妻天天添夜夜摸| 欧美日韩成人在线一区二区| 久久久久久久大尺度免费视频| 午夜老司机福利片| 一个人免费看片子| 免费av中文字幕在线| 尾随美女入室| 丁香六月欧美| 国产亚洲精品久久久久5区| a级毛片黄视频| 亚洲av国产av综合av卡| 另类精品久久| 亚洲伊人久久精品综合| 男女午夜视频在线观看| www.精华液| 黄片小视频在线播放| 日日夜夜操网爽| videosex国产| 老司机亚洲免费影院| 伊人亚洲综合成人网| 亚洲欧美日韩另类电影网站| 午夜av观看不卡| 自线自在国产av| 成人国语在线视频| 欧美变态另类bdsm刘玥| 黑人欧美特级aaaaaa片| 国产成人精品在线电影| 老司机影院成人| 婷婷色麻豆天堂久久| 亚洲成人免费电影在线观看 | 自线自在国产av| 国产97色在线日韩免费| 两个人免费观看高清视频| 精品第一国产精品| 亚洲精品美女久久av网站| 在线观看免费高清a一片| 亚洲人成77777在线视频| 欧美国产精品va在线观看不卡| 久久久亚洲精品成人影院| 在线观看www视频免费| 久久精品久久久久久噜噜老黄| 乱人伦中国视频| 成人国语在线视频| 午夜福利乱码中文字幕| 色视频在线一区二区三区| av福利片在线| 国产欧美日韩一区二区三区在线| 在线av久久热| 少妇被粗大的猛进出69影院| 午夜免费鲁丝| 亚洲av电影在线进入| 欧美国产精品va在线观看不卡| 这个男人来自地球电影免费观看| 久久久久久久大尺度免费视频| 国产成人一区二区三区免费视频网站 | 久久久国产精品麻豆| 亚洲精品国产av成人精品| 电影成人av| 妹子高潮喷水视频| 日韩一卡2卡3卡4卡2021年| 男女无遮挡免费网站观看| 亚洲情色 制服丝袜| videosex国产| 五月天丁香电影| 在线看a的网站| 99热全是精品| 国产极品粉嫩免费观看在线| 精品亚洲成a人片在线观看| 高清av免费在线| 国产91精品成人一区二区三区 | www.熟女人妻精品国产| 成年人免费黄色播放视频| 欧美日韩国产mv在线观看视频| 大话2 男鬼变身卡| 国产成人一区二区三区免费视频网站 | 狠狠婷婷综合久久久久久88av| 女性被躁到高潮视频| 欧美激情高清一区二区三区| 看免费av毛片| 在线av久久热| 一边摸一边做爽爽视频免费| 成人亚洲精品一区在线观看| 午夜久久久在线观看| 无遮挡黄片免费观看| 欧美日韩一级在线毛片| 亚洲欧美一区二区三区国产| 国产亚洲精品久久久久5区| 午夜福利视频精品| 欧美黑人欧美精品刺激| 日韩av免费高清视频| 十八禁高潮呻吟视频| 操出白浆在线播放| 超碰成人久久| 另类亚洲欧美激情| 黑人猛操日本美女一级片| 伊人久久大香线蕉亚洲五| 欧美xxⅹ黑人| 亚洲欧美一区二区三区久久| 亚洲国产日韩一区二区| 欧美日韩视频高清一区二区三区二| 久久天堂一区二区三区四区| 国产亚洲午夜精品一区二区久久| 91成人精品电影| 国产成人av教育| 在线观看人妻少妇| 日本vs欧美在线观看视频| 国产高清视频在线播放一区 | 国产有黄有色有爽视频| 精品久久久精品久久久| 精品免费久久久久久久清纯 | 欧美变态另类bdsm刘玥| 国产亚洲欧美精品永久| 国产亚洲精品第一综合不卡| 少妇人妻久久综合中文| 91成人精品电影| 可以免费在线观看a视频的电影网站| 久久狼人影院| 国产成人啪精品午夜网站| 日韩电影二区| 亚洲av电影在线观看一区二区三区| 日本黄色日本黄色录像| 久久精品国产综合久久久| 久久人妻福利社区极品人妻图片 | 国产av精品麻豆| 我要看黄色一级片免费的| 国产有黄有色有爽视频| 在现免费观看毛片| 欧美亚洲 丝袜 人妻 在线| 中文字幕亚洲精品专区| 久久这里只有精品19| 国产精品麻豆人妻色哟哟久久| 亚洲精品国产一区二区精华液| 久久亚洲国产成人精品v| 高潮久久久久久久久久久不卡| 色网站视频免费| 亚洲欧美中文字幕日韩二区| 久久免费观看电影| 免费看av在线观看网站| 婷婷色麻豆天堂久久| 老司机靠b影院| 99热网站在线观看| av在线app专区| 色综合欧美亚洲国产小说| 亚洲第一av免费看| 国产高清国产精品国产三级| 免费看不卡的av| 男男h啪啪无遮挡| 男女边摸边吃奶| 亚洲国产精品国产精品| www.熟女人妻精品国产| 美女脱内裤让男人舔精品视频| 少妇 在线观看| 免费不卡黄色视频| 黄片小视频在线播放| av电影中文网址| 男人操女人黄网站| 国产亚洲精品第一综合不卡| 欧美久久黑人一区二区| 男女免费视频国产| 亚洲精品国产av蜜桃| 大片电影免费在线观看免费| 亚洲av日韩精品久久久久久密 | 99精国产麻豆久久婷婷| 久久久精品区二区三区| 在线av久久热| 19禁男女啪啪无遮挡网站| 亚洲欧美一区二区三区国产| 两人在一起打扑克的视频| 国产精品二区激情视频| av不卡在线播放| 精品国产乱码久久久久久小说| 两个人免费观看高清视频| 一区二区三区乱码不卡18| 免费人妻精品一区二区三区视频| 免费少妇av软件| 精品高清国产在线一区| 欧美日韩成人在线一区二区| 日韩视频在线欧美| 精品少妇久久久久久888优播| 亚洲av日韩在线播放| 亚洲 国产 在线| 制服人妻中文乱码| 欧美xxⅹ黑人| 欧美+亚洲+日韩+国产| 成人18禁高潮啪啪吃奶动态图| 男女之事视频高清在线观看 | 免费人妻精品一区二区三区视频| 亚洲第一av免费看| 色播在线永久视频| 制服诱惑二区| 精品人妻在线不人妻| 欧美乱码精品一区二区三区| 午夜av观看不卡| 国产野战对白在线观看| 9色porny在线观看| 国产欧美亚洲国产| 曰老女人黄片| 国产97色在线日韩免费|